SULAR Drug Patent Profile
✉ Email this page to a colleague
When do Sular patents expire, and what generic alternatives are available?
Sular is a drug marketed by Covis and is included in one NDA.
The generic ingredient in SULAR is nisoldipine. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nisoldipine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sular
A generic version of SULAR was approved as nisoldipine by MYLAN on July 25th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SULAR?
- What are the global sales for SULAR?
- What is Average Wholesale Price for SULAR?
Summary for SULAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Patent Applications: | 3,996 |
| Drug Prices: | Drug price information for SULAR |
| What excipients (inactive ingredients) are in SULAR? | SULAR excipients list |
| DailyMed Link: | SULAR at DailyMed |
Pharmacology for SULAR
| Drug Class | Dihydropyridine Calcium Channel Blocker |
| Mechanism of Action | Calcium Channel Antagonists |
| Physiological Effect | Decreased Blood Pressure |
Paragraph IV (Patent) Challenges for SULAR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SULAR | Extended-release Tablets | nisoldipine | 8.5 mg and 17 mg | 020356 | 1 | 2009-03-02 |
| SULAR | Extended-release Tablets | nisoldipine | 25.5 mg and 34 mg | 020356 | 1 | 2008-11-28 |
| SULAR | Extended-release Tablets | nisoldipine | 20 mg and 30 mg | 020356 | 1 | 2007-11-07 |
| SULAR | Extended-release Tablets | nisoldipine | 40 mg | 020356 | 1 | 2007-06-11 |
US Patents and Regulatory Information for SULAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-008 | Jan 2, 2008 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-005 | Jan 2, 2008 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-002 | Feb 2, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-004 | Feb 2, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-001 | Feb 2, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SULAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-004 | Feb 2, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-005 | Jan 2, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-003 | Feb 2, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-008 | Jan 2, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-001 | Feb 2, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SULAR
See the table below for patents covering SULAR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 547931 | ⤷ Sign Up | |
| Greece | 3020404 | ⤷ Sign Up | |
| Canada | 2031393 | COMPRIMES A LIBERATION PROGRESSIVE DE SUBSTANCES ACTIVES (TABLETS WITH CONTROLLED-RATE RELEASE OF ACTIVE SUBSTANCES) | ⤷ Sign Up |
| Italy | 1237904 | COMPRESSE A RILASCIO A VELOCITA' CONTROLLATA DELLE SOSTANZE ATTIVE | ⤷ Sign Up |
| Ireland | 60352 | Press coated dhp tablets | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
